COGNITIVE DEFICIT IN PATIENTS WITH METABOLIC SYNDROME
- Authors: Shlshkova V.1, Osychenko M.2
-
Affiliations:
- Center for Speech Pathology and Neurorehabilitation
- Heaith Care Facility Sixty-Nine, Moscow
- Issue: Vol 23, No 3 (2012)
- Pages: 30
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115326
- ID: 115326
Cite item
Abstract
The timely detection and correction of cognitive impairments in patients with metabolic syndrome let us affect effectivelyall underlying disorders. Therapy with pyribedil (Pronoran) is successfully used to correctmoderate cognitive impairments in patients with metabolic disturbances.
Full Text
About the authors
V. Shlshkova
Center for Speech Pathology and Neurorehabilitation
Email: veronika-1306@mail.ru
M. Osychenko
Heaith Care Facility Sixty-Nine, Moscow
References
- Bonora E., Kiechl S., Willeit J. et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome // Diabetes Care. - 2003; 26 (4): 1251-1257.
- Ford E. Prevalence of the metabolic syndrome defined by the diabetes federation among adults in the U.S. // Diabetes Care. - 2005; 28: 2745-2749.
- International Diabetes Federation. The IDF consensus worldwidedefinition of the metabolic syndrome. Part 1: Worldwidedefinition for use in clinical practice. Berlin 2005. Available at: http://www.idf.org/webdata/docs/IDF_Metasyndrome_ definition.pdf.
- Мамедов М. H. Алгоритмы диагностики и лечения метаболического синдрома в клинико-амбулаторных условиях // Кардиология. - 2005; 5: 92-99.
- Чазова И. E., Мычка В. Б. Метаболический синдром. - М.: MediaMedica 2004. - 164 с.
- Awad N., Gagnon М., Messier С. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function // J. Clin. Exp. Neuropsychol. - 2004; 26: 1044-1080.
- Craft S. The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia // Arch. Neurol. - 2009; 66: 300-305.
- Schrijvers E., Witteman J., Sijbrands E. et al. Insulin metabolism and the risk of Alzheimer disease // The Rotterdam Study Neurology. - 2010; 75: 1982-1987.
- Biessels G., Staekenborg S., Brunner E. et al. Risk of dementia in diabetes mellitus: a systematic review // Lancet Neurol. - 2006; 5 (1): 64-74.
- Захаров В. В. Нейропсихологические тесты. Необходимость и возможность применения // Consilium Medicum. - 2011; 13 (2); 98-106.
- Чазова И.Е. Национальные рекомендации по диагностике и лечению метаболического синдрома // Кардиоваскулярная терапия и профилактика. - 2007; 6 (6) Приложение 2.
- Nagaraja D., Jayaashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment // Am. J. Psychiatry.— 2001; 158; 1517-1519.
- Bartoli G., Wichrowska E. Controlled clinical trial of piribedil in the treatment of cerebrovascular insufficiency // La Clinica Terapeutioca. - 1976; 78; 141-151.
- Захаров В. В., Локшина А. Б., Применение препарата проноран (пирибедил) при легких когнитивных расстройствах у пожилых больных с дисциркуляторной энцефалопатией // Неврол. журн. - 2004; 2; 30-35.
- Allard Р., Englund E., Marcusson J. Reduced number of caudate nucleus dopamine uptake sites in vascular dementia // Dementia. - 1999; 10: 77-80.
- Allard P., Englund E., Marcusson J. Caudate nucleus dopamine D.2 receptors in vascular dementia // Dementia and geriatric cognitive disorders. - 2002; 14; 22-25.
- Raz N., Rodrigue K., Acker J. Hypertension and the brain: Vulnerability of the prefrontal regions and executive functions // Behav. Neurosci. - 2003; 117; 1169-1180.
- Alexopoulos G. The depression-executive dysfunction syndrome of late life // Am.J. Geriatr. Psychiatry. - 2001; 9: 22-29.
- McIntyre R., Park K., Law C. et al. The Association between Conventional Antidepressants and the Metabolic Syndrome // CNS Drugs. - 2010; 24; 741-753.
- Gobert A., DiCara B., Cistarelly L. et al. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of a2-adrenoreceptors // J. Pharmacology and Experimental Therapeutics; 305(1); 338-346.